Mirikizumab effective in Crohn’s induction(blocks IL-23)

Looks like another medication similar to Stelara (Stelara blocks both IL-12 and IL-23) is making progress. Mirikizumab blocks IL-23. Another mab, monoclonal antibody biologic.

Bruce E. Sands, MD, of the Icahn School of Medicine at Mount Sinai, said agents that target the interleukin-23 pathway, like mirikizumab, have shown efficacy in CD. The drug has also shown success in treating ulcerative colitis and psoriasis.

“Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody, and it binds to the p19 subunit of IL-23,” Sands said in his presentation. “We assessed the safety and efficacy of mirikizumab with a phase 2, multi-center, randomized, parallel-arm, double-blind, placebo-controlled trial in patients with moderate-to-severely active Crohn’s disease.”

At week 12, in which 10.9% of patients achieved endoscopic response (95% CI, 3.3–18.6), response rates were better in all three mirikizumab groups vs. placebo. The 200 mg group experienced a 25.8% response rate (95% CI, 10.4–41.2), the 600 mg group achieved a 37.5% response rate (95% CI, 20.7–54.3) and the 1,000 mg group achieved a 43.8% response rate (95% CI, 31.6–55.9).

https://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/online/%7Bace1b763-9fc5-403c-b6b1-1a89d3d7eb15%7D/mirikizumab-effective-in-crohns-induction